Blog

按时交付：Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

Explore how PMx regulatory submissions, exposure-response modeling, and strategic pharmacometrics planning support successful and timely…

Certara2025 年 12 月 29 日

Conference

MVA Oncology Network

Certara2025 年 12 月 19 日

Announcement

Certara Announces New Release of Integral® Software

Latest version enhances efficiency, compliance, and user experience for PK scientists Radnor, PA. — December…

Danielle Pillsbury2025 年 12 月 16 日

Blog

Using M&S to Evaluate Oncology Drug Dosing

Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…

Certara2025 年 11 月 14 日

Blog

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…

Certara2025 年 11 月 13 日

On-Demand Webinar

Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®

Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…

Certara2025 年 11 月 13 日

Publication

Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema

Certara and Ionis analyzed Phase 3 OASIS-HAE data showing flexible, effective donidalorsen dosing can reduce…

Certara2025 年 11 月 12 日

Case Study

Supporting KalVista’s NDA Submission for a Novel HAE Treatment

To accelerate the first oral therapy for hereditary angioedema (HAE), KalVista Pharmaceuticals partnered with Certara…

Danielle Pillsbury2025 年 11 月 12 日

Case Study

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…

Certara2025 年 11 月 10 日

On-Demand Webinar

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

In today’s market where long development timelines and investor caution can slow progress, MIDD offers…

Certara2025 年 11 月 10 日

Modeling and Simulation – PK/PD

按时交付：Why Pharmacometrics (PMx) Is the Anchor of Successful Regulatory Submissions

MVA Oncology Network

Certara Announces New Release of Integral® Software

Using M&S to Evaluate Oncology Drug Dosing

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®

Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema

Supporting KalVista’s NDA Submission for a Novel HAE Treatment

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

订阅时事通讯

快捷链接

解决方案

联系我们